The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

By sjmartinez • October 20, 2023

Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Oct 19. doi: 10.1038/s41591-023-02593-0. Epub ahead of print. PMID: 37857711.

Tags: Hematology/Oncology, Publications

Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges

Nguyen J, Tun N, Burley N, Bolos D. Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges. Cureus. 2024 May 4;16(5):e59628. doi:[...]

Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma

Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]

Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank

Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]